These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3583222)

  • 41. [Evaluation of methylprednisolone pulse therapy versus combined therapy with prednisolone and cyclosporine in the treatment of infiltrative ophthalmopathy in Graves' disease].
    Dalmatova АВ; Grineva EN
    Probl Endokrinol (Mosk); 2007 Oct; 53(5):27-30. PubMed ID: 31627654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The mechanism of glucose intolerance in patients with Graves' disease].
    Kondo Y; Suzuki S; Gomi Y; Mayumi K; Sakamaki T; Inoue T; Iino S
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1257-68. PubMed ID: 1291337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of severe Graves' ophthalmopathy with cyclosporin A.
    Utech C; Wulle KG; Bieler EU; Pfannenstiel P; Panitz N; Kiefer H
    Acta Endocrinol (Copenh); 1985 Dec; 110(4):493-8. PubMed ID: 3911714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inequality of clearance values obtained by intravenous bolus and by steady-state infusion. Prednisolone studies in dogs.
    Frey FJ; Frey BM
    Pharmacology; 1982; 24(6):346-54. PubMed ID: 7111375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secretory IgA and lysozyme in tears of patients with Graves' ophthalmopathy.
    Khalil HA; De Keizer RJ; Bodelier VM; Kijlstra A
    Doc Ophthalmol; 1989 Aug; 72(3-4):329-34. PubMed ID: 2625093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic management of dysthyroid ophthalmopathy.
    Fells P
    Eye (Lond); 1988; 2 ( Pt 2)():198-200. PubMed ID: 3058526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Graves' disease following nephrotic syndrome treated by prednisolone: A case report.
    Narita C; Nishizaki N; Takubo N; Shimura N; Shimizu T
    Pediatr Int; 2023; 65(1):e15634. PubMed ID: 37804051
    [No Abstract]   [Full Text] [Related]  

  • 48. Plasma exchange in conjunction with immunosuppressive drug therapy in the treatment of endocrine exophthalmos.
    Sawers JS; Irvine WJ; Toft AD; Urbaniak SJ; Donaldson AA
    J Clin Lab Immunol; 1981 Nov; 6(3):245-50. PubMed ID: 6896074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prednisolone clearance at steady state in man.
    Legler UF; Frey FJ; Benet LZ
    J Clin Endocrinol Metab; 1982 Oct; 55(4):762-7. PubMed ID: 7107818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Choroidal folds in Graves' ophthalmopathy.
    Kowal L; Georgievski Z
    Aust N Z J Ophthalmol; 1994 Aug; 22(3):216. PubMed ID: 7818882
    [No Abstract]   [Full Text] [Related]  

  • 51. Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculo-erosive diseases.
    Lozada F; Frey FJ; Benet LZ
    J Dent Res; 1983 May; 62(5):575-7. PubMed ID: 6573375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methylprednisolone and Graves' ophthalmopathy.
    Dandona P; Havard CW; Mier A
    BMJ; 1989 Mar; 298(6676):830. PubMed ID: 2496877
    [No Abstract]   [Full Text] [Related]  

  • 53. Graves' ophthalmopathy requires early steroid therapy.
    Freiwald MJ; González C
    Pa Med; 1986 Feb; 89(2):42, 44. PubMed ID: 3754321
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetics of prednisolone in normal and asthmatic subjects in relation to dose.
    McAllister WA; Winfield CR; Collins JV
    Eur J Clin Pharmacol; 1981; 20(2):141-5. PubMed ID: 7262175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyrotoxicosis factitia complicating Graves' disease.
    Ferriss JB; Hooper MJ
    Ir J Med Sci; 1976 Dec; 145(1):260. PubMed ID: 27517241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans.
    Frey BM; Frey FJ
    Eur J Clin Invest; 1984 Feb; 14(1):1-6. PubMed ID: 6230241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.
    Tawara K; Kawashima K; Ishikawa H; Yamamoto K; Saito K; Ebihara A; Yoshida S
    Eur J Clin Pharmacol; 1981 Feb; 19(3):197-203. PubMed ID: 6894282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin therapy and Graves' ophthalmopathy.
    Krassas G; Kaltsas T; Pontikides N; Dumas A
    Thyroid; 1997 Jun; 7(3):489. PubMed ID: 9226222
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate.
    Derendorf H; Rohdewald P; Möllmann H; Rehder J; Barth J; Neveling D
    Biopharm Drug Dispos; 1985; 6(4):423-32. PubMed ID: 4084667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doesn't Graves' disease cause bulging eyes? My brother was diagnosed with Graves' disease several years ago, but his eyes appear to be unchanged.
    Mayo Clin Health Lett; 2012 Feb; 30(2):8. PubMed ID: 27024369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.